Advances in chemotherapy in advanced non-small-cell lung cancer

被引：47

作者：

Maione, Paolo ^{[1
]}

Rossi, Antonio ^{[1
]}

Sacco, Paola Claudia ^{[1
]}

Bareschino, Maria Anna ^{[1
]}

Schettino, Clorinda ^{[1
]}

Gridelli, Cesare ^{[1
]}

机构：

[1] SG Moscati Hosp, Div Med Oncol, I-83100 Avellino, Italy

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2010年 / 11卷 / 18期

关键词：

advanced NSCLC; bevacizumab; erlotinib; gefitinib; pemetrexed; platin-based chemotherapy; RANDOMIZED PHASE-III; GEMCITABINE PLUS CARBOPLATIN; 1ST-LINE CHEMOTHERAPY; BEVACIZUMAB; PACLITAXEL; TRIAL; CISPLATIN; THERAPY; ANTIFOLATE; GEFITINIB;

D O I：

10.1517/14656566.2010.511615

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Importance of the field: Lung cancer is the most common cancer in the world today, in terms of both incidence and mortality. Non-small-cell lung cancer (NSCLC) accounts for about 85% of all lung cancers diagnosis, and the majority of people diagnosed with NSCLC have advanced disease. Areas covered in this review: In this review the main advances achieved in the medical treatment of advanced NSCLC are discussed, regarding both targeted therapies and chemotherapy. Among targeted therapies, recent data on the anti-vascular endothelial growth factor (VEGF) monoclonal antibody bevacizumab and the epidermal growth factor receptor tyrosyne kinase inhibitors (EGFR-TKIs) gefitinib and erlotinib are described. Among chemotherapeutic agents, the role of pemetrexed is discussed. What the reader will gain: The reader will gain up-to-date information on the main advances, achieved in the last 3 years in the medical treatment of advanced NSCLC. Take home message: Some recent advances have changed the face of the first-line chemotherapy of advanced NSCLC, giving physicians more options to tailor choice in this challenging setting.

引用

页码：2997 / 3007

页数：11

共 50 条

[41] Evaluation of Amrubicin as a Third or Later Line of Chemotherapy for Advanced Non-Small Cell Lung Cancer [J].

Igawa, Satoshi ;

Sasaki, Jiichiro ;

Ishihara, Mikiko ;

Otani, Sakiko ;

Maki, Sachiyo ;

Hiyoshi, Yasuhiro ;

Kasajima, Masashi ;

Katono, Ken ;

Takakura, Akira ;

Masuda, Noriyuki .

CHEMOTHERAPY, 2013, 59 (02) :99-105

[42] Chemotherapy for advanced non-small cell lung cancer with a focus on squamous cell carcinoma [J].

Kuribayashi, Kozo ;

Funaguchi, Norihiko ;

Nakano, Takashi .

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (02) :528-534

[43] Cost-Effectiveness Analysis of Gefitinib Plus Chemotherapy versus Gefitinib Alone for Advanced Non-Small-Cell Lung Cancer with EGFR Mutations in China [J].

Shu, Yamin ;

Zhang, Qilin ;

He, Xucheng ;

Chen, Li .

CANCER MANAGEMENT AND RESEARCH, 2021, 13 :8297-8306

[44] Safety and efficacy of nivolumab and standard chemotherapy drug combination in patients with advanced non-small-cell lung cancer: a four arms phase Ib study [J].

Kanda, S. ;

Goto, K. ;

Shiraishi, H. ;

Kubo, E. ;

Tanaka, A. ;

Utsumi, H. ;

Sunami, K. ;

Kitazono, S. ;

Mizugaki, H. ;

Horinouchi, H. ;

Fujiwara, Y. ;

Nokihara, H. ;

Yamamoto, N. ;

Hozumi, H. ;

Tamura, T. .

ANNALS OF ONCOLOGY, 2016, 27 (12) :2242-2250

[45] Factors of interrupting chemotherapy in patients with advanced non-small-cell lung cancer [J].

Belbaraka R. ;

Trédan O. ;

Ray-Coquard I. ;

Chvetzoff G. ;

Bajard A. ;

Pérol D. ;

Ismaili N. ;

Ismaili M. ;

Errihani H. ;

Bachelot T. ;

Rebattu P. .

BMC Research Notes, 3 (1)

[46] Endothelial progenitor cells are associated with response to chemotherapy in human non-small-cell lung cancer [J].

Morita, Ryo ;

Sato, Kazuhiro ;

Nakano, Mariko ;

Miura, Hajime ;

Odaka, Hidesato ;

Nobori, Kiyoshi ;

Kosaka, Toshimitsu ;

Sano, Masaaki ;

Watanabe, Hiroyuki ;

Shioya, Takanobu ;

Ito, Hiroshi .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (12) :1849-1857

[47] Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: A systematic review and meta-analysis [J].

Lin, Hao ;

Jiang, Jingwei ;

Liang, Xiaohua ;

Zhou, Xinli ;

Huang, Ruofan .

LUNG CANCER, 2010, 70 (01) :57-62

[48] Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer [J].

Bondarenko, Igor M. ;

Ingrosso, Antonella ;

Bycott, Paul ;

Kim, Sinil ;

Cebotaru, Cristina L. .

BMC CANCER, 2015, 15

[49] Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer [J].

Menter, Alex R. ;

Carroll, Nikki M. ;

Sakoda, Lori C. ;

Delate, Thomas ;

Hornbrook, Mark C. ;

Jain, Rakesh K. ;

Kushi, Lawrence H. ;

Quinn, Virginia P. ;

Ritzwoller, Debra P. .

CLINICAL LUNG CANCER, 2017, 18 (02) :189-+

[50] Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting [J].

Li, Jianjie ;

Chi, Yujia ;

Cao, Guang ;

Zhao, Jun ;

An, Tongtong ;

Wu, Meina ;

Wang, Yuyan ;

Zhuo, Minglei ;

Yang, Xue ;

Jia, Bo ;

Chen, Hanxiao ;

Wang, Jingjing ;

Zhai, Xiaoyu ;

Wang, Ziping .

JOURNAL OF THORACIC DISEASE, 2021, 13 (03) :1813-1821

← 1 2 3 4 5 →